NOTV Overview

Oversold Stocks in Health Care: The health care sector has several oversold stocks, presenting potential buying opportunities for undervalued companies, particularly those with a Relative Strength Index (RSI) below 30.

Inotiv Inc Performance: Inotiv Inc reported strong contract awards and anticipates fourth-quarter revenue between $137.5 million and $138.5 million, despite its stock falling 38% recently, with an RSI of 26.7.

Airsculpt Technologies Update: Airsculpt Technologies faced disappointing third-quarter results and lowered its FY25 revenue outlook, leading to a 60% stock drop over the past month, with an RSI of 29.3.

Neuronetics Sales Guidance: Neuronetics cut its FY2025 sales guidance, resulting in a 40% decline in stock value over the past month, and it currently has an RSI of 23.9.

Gorilla Technology Group Performance: Gorilla Technology Group Inc. reported a 32% year-over-year revenue increase to $26.5 million for Q3, leading to a 13.7% rise in its share price during pre-market trading.

Other Gainers in Pre-Market Trading: Notable stocks that surged include Olema Pharmaceuticals (up 53%), Lobo Technologies (up 40.3%), and Aspire Biopharma (up 30.7%), among others.

Losers in Pre-Market Trading: LifeMD Inc. saw a significant drop of 26.2% after disappointing financial results, while Alpha Technology Group and NextPlat Corp also experienced notable declines.

Market Overview: The pre-market trading session showed a mix of gains and losses across various stocks, with some companies reporting strong earnings while others faced setbacks.

Stock Performance: Inotiv, Inc. (NOTV) shares surged over 23% in overnight trading following the release of preliminary fiscal Q4 and full-year results for 2025.

Revenue Growth: The company anticipates Q4 2025 revenue between $137.5 million and $138.5 million, marking a 6% increase year-over-year, with full-year revenue expected to be slightly above $512.5 million.

Service Momentum: Inotiv reported a significant 60% year-over-year growth in its Discovery and Safety Assessment (DSA) services for Q4, alongside a book-to-bill ratio of approximately 1.08x for Q4.

Future Outlook: CEO Robert Leasure Jr. emphasized ongoing financial goals and improvements in revenue visibility, with final audited results set to be released in early December and a presentation scheduled at the Jefferies Global Healthcare Conference on November 18, 2025.